Suneva Medical has announced it has completed a $20.4 million growth-capital term loan with an account managed by HealthCare Royalty Partners. Suneva has closed a $15 million equity investment by Almirall, Inc., an affiliate of Almirall, S.A, a global pharmaceutical company.

Suneva markets Bellafill, the only dermal filler on the market that is FDA approved for the correction of facial acne scars.

"We are enthusiastic about the potential this strategic relationship with Almirall creates as we continue to grow. We look forward to the opportunities with Almirall to energize and expand our business," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "The Almirall equity investment will accelerate the growth for our current product portfolio and allow us the flexibility to continue to build one of the industry's leading, fully integrated aesthetics companies."

Eduardo Sanchiz, Almirall's Chief Executive Officer, also commented on the investment: "We are very pleased to perform this strategic investment in Suneva Medical. Almirall is looking for attractive business development opportunities in the dermatology field and this represents our first investment in the aesthetics area. We have been attracted by the quality of Suneva's portfolio and its management team. This partnership will also allow us to further build our understanding of the performance of the aesthetics dermatology market in the U.S."